A
Aulisa Medical
Wireless, wearable vital signs monitoring systems for patients
About Aulisa Medical
Aulisa Medical integrates medical device science with information communication technologies to create smart medical solutions. Founded in 2012 by serial entrepreneur Augustine (Augie) Lien, the company was first based in Palo Alto, California. In 2013, a headquarters for R&D, manufacturing, and other operations was established in Taipei, Taiwan, with Aulisa Medical USA, Inc. incorporated in 2018 as a subsidiary for US marketing and sales.
Augie Lien, who holds an MS from Stanford University and an MBA from Santa Clara University, has a track record of founding successful medical device companies, including Nellcor (acquired by Medtronic), Menlo Care (merged with Johnson & Johnson), and Cardiva Medical (acquired by Haemonetics). This background in patient monitoring and interventional cardiology informed the creation of Aulisa.
The company specializes in developing FDA-cleared, wireless, and wearable vital sign monitoring systems for both clinical and at-home use. Its core product line, the Guardian Angel® series, uses pulse oximetry to continuously track key vitals like blood oxygen saturation (SpO2) and heart rate for adult, pediatric, and infant patients. These devices are designed to address the inconsistencies of intermittent spot-checking by providing continuous, cloud-based data and customizable alarms that alert caregivers to potential adverse events. This allows for earlier intervention and provides medical professionals with recorded data to better analyze patient conditions. The business model includes direct-to-consumer sales via its website and Amazon, as well as leasing plans for healthcare facilities, making advanced technology accessible without large upfront costs. Revenue is also generated through a Series A funding round of $13 million in 2022.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2022 | $13M | $52M | Undisclosed | ↗ |
| SEEDEquity / VC | Jan 2014 | $0 | — | WI Harper Group | — |
Growth signals
Latest recorded traffic for Aulisa Medical is 2.4K monthly website visits, up 84.6% over the last three months. Aulisa Medical's team grew 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aulisa Medical in the Palo Alto ecosystem
The Aulisa Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
WI Harper Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aulisa Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aulisa Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








